General description
BGP-15 is a hydroxylamine derivative, which has cytoprotective and neuroprotective properties. It reduces phospho- c-Jun N-terminal kinase (pJNK) and p38 stress signalling. BGP-15 also stimulates non-specific serine/threonine protein kinase (AKT) and insulin-like growth factor 1 receptor (IGFR1) protective signalling. BGP-15 functions as an insulin sensitizer in an olanzapine-induced metabolic disorder. It protects cells against cell death and enhances the expression of heat shock protein (HSP). BGP-15 might be used to treat heart failure (HF) and atrial fibrillation (AF).
Application
BGP-15 has been used to study its influence on proteasomal degradation of missense dystrophins.
Biochem/physiol Actions
BGP-15 is PARP inhibitor, HSP72 activator.
BGP-15 is PARP inhibitor, HSP72 activator.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | solid |
| solubility | deionized water: 28 mg/mL |
| storage temp. | −20°C |
| SMILES string | Cl.Cl.N\C(=N/OCC(O)CN1CCCCC1)c2cccnc2 |
| InChI | 1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H |
| InChI key | ISGGVCWFTPTHIX-UHFFFAOYSA-N |
